Oncology/Hematology
Myeloma
More in Myeloma
High rates of deep, durable response with bispecific antibody, rapidly produced CAR T-cell agents
Jun 05, 2023
Ciltacabtagene autoleucel improved progression-free survival versus two standard triplets
Jun 05, 2023
Researchers say safety, efficacy of ALLO-715 comparable to autologous anti-BCMA products
Feb 02, 2023
Produced an antiviral response in 95% of patients with six different types of infection
Jan 13, 2023
Continuing Medical Education
1.00 CME Credits